Epigenetic biomarkers for smoking cessation

Area of Science:

• Epigenetics
• Molecular Biology
• Public Health

Background:

• Cigarette smoking induces epigenetic alterations, particularly DNA methylation.
• DNA methylation changes are linked to smoking exposure and adverse health outcomes.
• These epigenetic modifications may be reversible upon smoking cessation.

Purpose of the Study:

• To review the reversibility of DNA methylation in peripheral tissues after smoking cessation.
• To assess the utility of DNA methylation as a biomarker for smoking status and time since cessation.
• To identify gaps in current research on smoking cessation epigenetics.

Main Methods:

• Systematic review of candidate gene and epigenome-wide association studies.
• Analysis of differentially methylated Cytosine-Guanine (CpG) dinucleotides and regions.
• Evaluation of multi-CpG predictors for smoking status.

Main Results:

• Robust evidence supports a DNA methylation signature for smoking cessation.
• Thousands of CpG sites and regions show differential methylation related to cessation.
• Multi-CpG predictors demonstrate accuracy in identifying smoking status.

Conclusions:

• DNA methylation serves as a reliable biomarker for smoking cessation.
• Gaps include cell-type heterogeneity, population diversity, longitudinal data, and other epigenetic marks.
• Further research with larger, diverse, longitudinal cohorts is needed for clinical biomarker development.